Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Saroja Pharma Industries India Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹0.00
High
₹0.00
Price Summary
| Previous Close | ₹33.00 |
|---|---|
| Day's Range | ₹0.00 - ₹0.00 |
| Open | ₹0.00 |
| 52 Week Range | ₹28.00 - ₹60.00 |
| Volume | 0 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 12.83 |
| TTM EPS (₹) | 2.57 |
| P/E Ratio | 14.68 |
| Book Value(₹) | 0.85 |
| PAT Margin (%) | 1.92 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 12.56 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | N/A | 408.62 |
| Expenses | N/A | N/A |
| PBT | N/A | 12.07 |
| Operating profit | N/A | 0.0 |
| Net profit | N/A | 8.78 |
About Saroja Pharma Industries India Ltd.
| Founded | 2019 |
|---|---|
| Managing Director | Biju Nair |
| NSE Symbol | SAROJA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,40,134.01 | 1,836.20 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,77,883.86 | 6,679.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,47,526.68 | 4,351.05 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,12,696.26 | 8,010.00 | 6,677.50 - 6,677.50 |
| Lupin Ltd. | 1,12,463.67 | 2,411.95 | 1,836.80 - 1,836.80 |
| Cipla Ltd. | 1,10,088.66 | 1,351.30 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,09,072.97 | 1,296.00 | 1,138.50 - 1,138.50 |
| Max Healthcare Institute Ltd. | 98,793.98 | 1,016.20 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 98,063.24 | 2,432.15 | 1,909.70 - 1,909.70 |
| Zydus Lifesciences Ltd. | 94,596.06 | 942.15 | 835.50 - 835.50 |
No Records Found
Latest News
May
8
2026
Posted on May 8th 2026
Indoco Remedies - Quaterly Results
The sales for the March 2026 quarter moved up 29.34% to Rs. 4491.30 millions as compared to Rs. 3472.50 millions during the corresponding quarter last year.The Total Profit for the quarter ended March 2026 of Rs. 273.50 millions grew from Rs.-262.40 millionsOperating profit surged to 733.80 millions from the corresponding previous quarter of 99.60 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 4491.30 | 3472.50 | 29.34 | 16860.70 | 15181.90 | 11.06 | 16860.70 | 15181.90 | 11.06 |
| Other Income | 103.50 | 65.00 | 59.23 | 296.40 | 184.80 | 60.39 | 296.40 | 184.80 | 60.39 |
| PBIDT | 733.80 | 99.60 | 636.75 | 1867.90 | 1465.20 | 27.48 | 1867.90 | 1465.20 | 27.48 |
| Interest | 227.30 | 159.80 | 42.24 | 885.00 | 566.30 | 56.28 | 885.00 | 566.30 | 56.28 |
| PBDT | 543.30 | -60.20 | -1002.49 | 954.30 | 908.80 | 5.01 | 954.30 | 908.80 | 5.01 |
| Depreciation | 267.10 | 248.80 | 7.36 | 1069.00 | 982.50 | 8.80 | 1069.00 | 982.50 | 8.80 |
| PBT | 276.20 | -309.00 | -189.39 | -114.70 | -73.70 | 55.63 | -114.70 | -73.70 | 55.63 |
| TAX | 2.70 | -46.60 | -105.79 | -58.10 | 13.60 | -527.21 | -58.10 | 13.60 | -527.21 |
| Deferred Tax | -26.50 | -17.30 | 53.18 | -87.30 | 13.60 | -741.91 | -87.30 | 13.60 | -741.91 |
| PAT | 273.50 | -262.40 | -204.23 | -56.60 | -87.30 | -35.17 | -56.60 | -87.30 | -35.17 |
| Equity | 184.60 | 184.50 | 0.05 | 184.60 | 184.50 | 0.05 | 184.60 | 184.50 | 0.05 |
| PBIDTM(%) | 16.34 | 2.87 | 469.63 | 11.08 | 9.65 | 14.79 | 11.08 | 9.65 | 14.79 |
Read More
May
8
2026
Posted on May 8th 2026
Thyrocare Tech. - Quaterly Results
The Revenue for the quarter ended March 2026 of Rs. 2106.70 millions grew by 21.17 % from Rs. 1738.70 millions.Profit for the quarter ended March 2026 rises by 98.54% to Rs. 435.80 millions from Rs. 219.50 millions.The company reported a good operating profit of 763.50 millions compared to 601.80 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 2106.70 | 1738.70 | 21.17 | 7742.70 | 6331.00 | 22.30 | 7742.70 | 6331.00 | 22.30 |
| Other Income | 37.20 | 45.40 | -18.06 | 133.90 | 133.40 | 0.37 | 133.90 | 133.40 | 0.37 |
| PBIDT | 763.50 | 601.80 | 26.87 | 2697.20 | 2003.60 | 34.62 | 2697.20 | 2003.60 | 34.62 |
| Interest | 14.30 | 6.00 | 138.33 | 21.80 | 26.30 | -17.11 | 21.80 | 26.30 | -17.11 |
| PBDT | 749.20 | 595.80 | 25.75 | 2615.70 | 1977.30 | 32.29 | 2615.70 | 1977.30 | 32.29 |
| Depreciation | 129.40 | 117.80 | 9.85 | 511.70 | 465.20 | 10.00 | 511.70 | 465.20 | 10.00 |
| PBT | 619.80 | 478.00 | 29.67 | 2104.00 | 1512.10 | 39.14 | 2104.00 | 1512.10 | 39.14 |
| TAX | 184.00 | 258.50 | -28.82 | 615.90 | 554.30 | 11.11 | 615.90 | 554.30 | 11.11 |
| Deferred Tax | 23.50 | 114.20 | -79.42 | 43.00 | 76.60 | -43.86 | 43.00 | 76.60 | -43.86 |
| PAT | 435.80 | 219.50 | 98.54 | 1488.10 | 957.80 | 55.37 | 1488.10 | 957.80 | 55.37 |
| Equity | 1591.70 | 529.90 | 200.38 | 1591.70 | 529.90 | 200.38 | 1591.70 | 529.90 | 200.38 |
| PBIDTM(%) | 36.24 | 34.61 | 4.71 | 34.84 | 31.65 | 10.07 | 34.84 | 31.65 | 10.07 |
Read More
May
8
2026
Posted on May 8th 2026
Innova Captab - Quaterly Results
The Sales for the quarter ended March 2026 of Rs. 3582.77 millions rose by 47.73% from Rs. 2425.22 millions.Modest increase of 23.57% in the Net Profit was reported from. 171.25 millions to Rs. 211.62 millions.Operating profit surged to 413.19 millions from the corresponding previous quarter of 325.36 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 3582.77 | 2425.22 | 47.73 | 12988.14 | 9580.61 | 35.57 | 12988.14 | 9580.61 | 35.57 |
| Other Income | 26.80 | 43.56 | -38.48 | 132.43 | 167.75 | -21.06 | 132.43 | 167.75 | -21.06 |
| PBIDT | 413.19 | 325.36 | 26.99 | 1646.10 | 1390.74 | 18.36 | 1646.10 | 1390.74 | 18.36 |
| Interest | 39.81 | 18.69 | 113.00 | 154.21 | 21.68 | 611.30 | 154.21 | 21.68 | 611.30 |
| PBDT | 373.38 | 306.67 | 21.75 | 1491.89 | 1369.06 | 8.97 | 1491.89 | 1369.06 | 8.97 |
| Depreciation | 94.03 | 78.12 | 20.37 | 373.67 | 170.15 | 119.61 | 373.67 | 170.15 | 119.61 |
| PBT | 279.35 | 228.55 | 22.23 | 1118.22 | 1198.91 | -6.73 | 1118.22 | 1198.91 | -6.73 |
| TAX | 67.73 | 57.30 | 18.20 | 281.30 | 304.21 | -7.53 | 281.30 | 304.21 | -7.53 |
| Deferred Tax | 58.38 | 29.89 | 95.32 | 103.65 | 84.21 | 23.09 | 103.65 | 84.21 | 23.09 |
| PAT | 211.62 | 171.25 | 23.57 | 836.92 | 894.70 | -6.46 | 836.92 | 894.70 | -6.46 |
| Equity | 572.25 | 572.25 | 0.00 | 572.25 | 572.25 | 0.00 | 572.25 | 572.25 | 0.00 |
| PBIDTM(%) | 11.53 | 13.42 | -14.04 | 12.67 | 14.52 | -12.69 | 12.67 | 14.52 | -12.69 |
Read More
May
7
2026
Posted on May 7th 2026
Global Longlife Hospital and Research informs about outcome of board meeting
In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Global Longlife Hospital and Research has informed that in the Board Meeting held today on Thursday, May 07, 2026, the Board of Directors of the Company has considered and approved the following matters: 1. Audited Financial Results for the Half Year and Year ended March 31, 2026 along with the Audit Report. 2. Alteration of name clause of Memorandum of Association of the company from Global Longlife Hospital and Research to Kanzi Enterprise or Asahi Enterprise or Siddhaa Enterprise, subject to the approval of shareholders of the company and ministry of corporate affairs. 3. Alteration in Clause III (A): the Main Object Clause of Memorandum of Association (‘MOA’) of the Company, subject to approval of Members. (The existing Clause III (A) will be deleted representing health care industry and new Clause III (A) will be added representing trade and service industry). The above matter has been duly approved by the Board of Directors at their meeting which commenced at 02:00 pm and concluded at 03:45 pm. The company has informed that, R B Gohil & Co., Chartered Accountants, Statutory Auditors have issued their Audit Reports with unmodified opinion on Audited Financial Results for the year ended March 31, 2026. In this connection, it has enclosed Audited Financial Results for the Half year and Year ended on March 31, 2026, Audit Report and the declaration that Auditor's Report on the results is with unmodified opinion (as Annexure-1). The same will be made available on the Company's website www.globalhospital.co.in.
The above information is a part of company’s filings submitted to BSE.
Read More
May
7
2026
Posted on May 7th 2026
Panacea Biotec informs about updates
Panacea Biotec has informed that it enclosed details of shares dematerialised during April 2026 under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
The above information is a part of company’s filings submitted to BSE.
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Saroja Pharma Industries India Ltd. is ₹33.00 as of 2026-05-08.
The market capitalisation of Saroja Pharma Industries India Ltd. is ₹13.27 as of 2026-04-28.
The 1-year return of Saroja Pharma Industries India Ltd. is 0.00% as of 2026-05-08.
The P/E ratio of Saroja Pharma Industries India Ltd. is 14.68 as of 2026-05-08.
The 52-week high and low of Saroja Pharma Industries India Ltd. are ₹60.00 and ₹28.00, respectively, as of 2026-05-08.
View More
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Personal Loan
My Accounts
Explore